The UAB Comprehensive Cancer Center Senior Leadership is comprised of seven individuals supported by the CCSG: Director - Edward E. Partridge, IVI.D. Deputy Director- Boris C. Pasche, M.D., Ph.D. Associate Director for Basic Research - Etty (Tika) Benveniste, Ph.D. Associate Director for Translational Research - Mary-Ann Bjornsti, Ph.D. Associate Director for Clinical Research - Albert F. LoBuglio, M.D. Associate Director for Prevention and Control - Wendy Demark-Wahnefried, Ph.D. Associate Director for Administration - Michael J. Bertram, Ph.D. There have been major changes in Senior Leadership since the last competitive renewal. Following a national search for a new Director, Dr. Edward E. Partridge was named Director in July of 2007. Dr. Partridge has a longstanding history in the UAB Comprehensive Cancer Center (UAB CCC) and has played various leadership roles over the past two decades. His primary areas of expertise include clinical and cancer control research. Other new Senior Leaders include Dr. Boris C. Pasche as Deputy Director, replacing Dr. Kirby Bland, now Senior Advisor to the Director;Dr. Etty Benveniste as Associate Director for Basic Research, replacing Dr. Robert Diasio, now Director of the Mayo Comprehensive Cancer Center;Dr. Albert LoBuglio as Associate Director for Clinical Research, following Dr. Sam Beenken's departure;Dr. Mary-Ann Bjornsti to the newly created position of Associate Director for Translational Research;Dr. Wendy Demark-Wahnefried as Associate Director for Prevention and Control, replacing Dr. Partridge;and Dr. Michael Bertram as Associate Director for Administration.

Public Health Relevance

Because of the investment of the National Cancer Institute in a Comprehensive Cancer Center, the center needs leadership that understands stewardship of public trust. The UAB CCC leadership's mission is to assure that the center fulfills the NCI goals of reducing morbidity and mortality from cancer;discovering the nature of cancer;understanding cancer biology;developing effective prevention, diagnosis, and therapy.; delivering medical advances to patients and their families;educating healthcare professionals and the public; and reaching out to underserved populations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA013148-42
Application #
8738159
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
42
Fiscal Year
2014
Total Cost
$298,559
Indirect Cost
$63,251
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Geng, Mengxin; Austin, Frank; Shin, Ronald et al. (2018) Covalent Structure and Bioactivity of the Type AII Lantibiotic Salivaricin A2. Appl Environ Microbiol 84:
Samykutty, Abhilash; Grizzle, William E; Fouts, Benjamin L et al. (2018) Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticle. Biomaterials 182:114-126
Friedman, Gregory K; Bernstock, Joshua D; Chen, Dongquan et al. (2018) Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression. Sci Rep 8:13930
Powell, T Clark; Dilley, Sarah E; Bae, Sejong et al. (2018) The Impact of Racial, Geographic, and Socioeconomic Risk Factors on the Development of Advanced-Stage Cervical Cancer. J Low Genit Tract Dis 22:269-273
Kasten, Benjamin B; Oliver, Patsy G; Kim, Harrison et al. (2018) 212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. Int J Mol Sci 19:
Subramaniam, Akila; Blanchard, Christina T; Erickson, Britt K et al. (2018) Feasibility of Complete Salpingectomy Compared With Standard Postpartum Tubal Ligation at Cesarean Delivery: A Randomized Controlled Trial. Obstet Gynecol 132:20-27
Garner, Evan F; Williams, Adele P; Stafman, Laura L et al. (2018) FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts. Sci Rep 8:6913
Stoll, Matthew L; Weiss, Pamela F; Weiss, Jennifer E et al. (2018) Age and fecal microbial strain-specific differences in patients with spondyloarthritis. Arthritis Res Ther 20:14
Locke, Landon W; Kothandaraman, Shankaran; Tweedle, Michael et al. (2018) Use of a leukocyte-targeted peptide probe as a potential tracer for imaging the tuberculosis granuloma. Tuberculosis (Edinb) 108:201-210
Fancy, Romone M; Kim, Harrison; Napier, Tiara et al. (2018) Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells. J Cell Biochem 119:6216-6230

Showing the most recent 10 out of 747 publications